Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world ...

Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and ...

In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, outlines her five-year vision for ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

Why a fundamental reimagining of how clinical studies operate is still necessary to achieve a true paradigm shift—and shed ...

A new global report finds that clinical research teams are making progress but still lack the skills and tools needed to keep ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in ...

Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia ...

In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, reflects on the company’s three-year evolution ...